Ecnoglutide, a once-weekly GLP-1 receptor agonist, demonstrated significant weight loss and health improvements in a phase 3 trial involving 664 adults in China with overweight or obesity. Over 48 weeks, the highest dose (2.4 mg) showed a 15.4% reduction in body weight and improved secondary outcomes such as cardiovascular risk factors and quality of life. Though mild gastrointestinal side effects were common, the treatment was well tolerated, indicating potential for long-term weight management. Further research is needed to confirm results across diverse populations.